ArticleGene therapy2006
Efficient immunization of rhesus macaques with an HCV candidate vaccine by heterologous priming-boosting with novel adenoviral vectors based on different serotypes.
Article in Gene therapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 47 citations in OpenAlex.
- Viral hepatitis update: Progress and perspectives.World journal of gastroenterology · 2021Review
- Use of an Outbred Rat Hepacivirus Challenge Model for Design and Evaluation of Efficacy of Different Immunization Strategies for Hepatitis C Virus.Hepatology (Baltimore, Md.) · 2020Article
- Challenges and Promise of a Hepatitis C Virus Vaccine.Cold Spring Harbor perspectives in medicine · 2020Review
- Approaches, Progress, and Challenges to Hepatitis C Vaccine Development.Gastroenterology · 2019Review
- Translational Aspects of Adeno-Associated Virus-Mediated Cardiac Gene Therapy.Human gene therapy · 2018Review
- Global elimination of hepatitis C virus infection: Progresses and the remaining challenges.World journal of hepatology · 2017Review
- Simian adenoviruses as vaccine vectors.Future virology · 2016Review
- Progress in the development of vaccines for hepatitis C virus infection.World journal of gastroenterology · 2015Review
- Will there be a vaccine to prevent HCV infection?Seminars in liver disease · 2014Review
- Strong vaccine-induced CD8 T-cell responses have cytolytic function in a chimpanzee clearing HCV infection.PloS one · 2014Article
- Genetic vaccine for respiratory syncytial virus provides protection without disease potentiation.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- The novel replication-defective vaccinia virus (Tiantan strain)-based hepatitis C virus vaccine induces robust immunity in macaques.Molecular therapy : the journal of the American Society of Gene Therapy · 2013Article
- Ever closer to a prophylactic vaccine for HCV.Expert opinion on biological therapy · 2013Review
- Construction and preparation of three recombinant adenoviruses expressing truncated NS3 and core genes of hepatitis C virus for vaccine purposes.Hepatitis monthly · 2012Article
- Review
- Article
- Article
- Viruses as vaccine vectors for infectious diseases and cancer.Nature reviews. Microbiology · 2010Review
- Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice.Infection and immunity · 2009Article
- New insights on adenovirus as vaccine vectors.Molecular therapy : the journal of the American Society of Gene Therapy · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Efficient vaccination against viral agents requires a strong T-cell-mediated immune response to clear viral-infected cells. Optimal vaccination can be achieved by administration of recombinant viral vectors encoding phatogen antigens. Adenoviral vectors have attracted considerable attention as potential viral vectors for genetic vaccination owing to their favorable safety profile and potent transduction efficiency following intramuscular injection. However, the neutralizing antibody response against adenoviral capsid proteins following adenoviral vectors injection limits the success of vaccination protocols based on multiple administrations of the same adenoviral serotype. In this work, we describe efficient immunization of rhesus macaques, the preferred model for preclinical assessment, with an HCV candidate vaccine by heterologous priming-boosting with adenoviral vectors based on different serotypes. The induced responses are broad and show significant cross-strain reactivity. Boosting can be delayed for over 2 years after priming, indicating that there is long-term maintenance of resting memory cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.